Company intelligence / Profile preview

Jiangsu Vcare PharmaTech Co., Ltd.

Nanjing, Jiangsu, Chinaen.vcarepharmatech.com ↗

Ownership: Private
Employees: ~1000
Development stage: NDA

Overview

Jiangsu Vcare has completed enrollment in Phase III clinical trial of antiplatelet drug Vicagrel in China, evaluating its efficacy and safety compared to Clopidogrel in patients with acute coronary syndrome. Their second-generation highly selective JAK1 inhibitor, VC005 tablets, received IND approval for oral treatment of non-segmental vitiligo from NMPA in May 2025[6].

Therapeutic areas: OncologyCardiovascularRheumatologyDermatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

becondogrel

Unknown

Beyond the preview

Go deeper on Jiangsu Vcare PharmaTech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Vcare PharmaTech Co., Ltd..

Explore the full profile